Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2018
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Pharmacodynamics
- 05 Mar 2018 Status changed from active, no longer recruiting to completed.
- 18 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 20 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Apr 2017 as per ClinicalTrials.gov record.